New drug combo aimed at helping smokers with schizophrenia

NCT ID NCT06374290

Terminated Disease control Sponsor: The University of Texas Health Science Center, Houston Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early pilot study tested whether a combination of injectable naltrexone and oral bupropion could help people with schizophrenia who smoke cigarettes. Only 2 participants were enrolled before the study was terminated. The main goals were to see if the treatment was feasible and safe, and to measure changes in smoking habits and schizophrenia symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: naltrexone (injectable) and bupropion (oral)
What this could lead to: If it works, this could point toward a new treatment option to help people with schizophrenia quit smoking.
What could go wrong: This was a very small pilot study (only 2 participants) that was terminated early, so results are limited. It is too early to know if the combination is effective or safe for this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia Smoking Cessation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMOKING CESSATION

Contacts and locations

Locations

The University of Texas health Science Center at Houston

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.